Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc.
Your view on VVOS
Overview
What the company does, where it operates, and who runs it.
About Vivos Therapeutics, Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- R. Kirk Huntsman
- Headquarters
- 9137 Ridgeline Boulevard, Highlands Ranch, CO, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- R. Kirk Huntsman
- Headquarters
- 9137 Ridgeline Boulevard, Highlands Ranch, CO, US
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children.
The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vivos Therapeutics, Inc., and the rating behind it. VVOS last traded at $0.18; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vivos Therapeutics, Inc.. Starting points for Vivos Therapeutics, Inc.: EPS -$1.45, beta 6.00 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vivos Therapeutics, Inc.. Vivos Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vivos Therapeutics, Inc.. Trailing twelve-month EPS for Vivos Therapeutics, Inc. stands at -$1.45. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vivos Therapeutics, Inc.. Vivos Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vivos Therapeutics, Inc. valued side by side against its closest peers. Vivos Therapeutics, Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vivos Therapeutics, Inc., and how their positions are changing. At a $2.6M market value, institutional positions materially move Vivos Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vivos Therapeutics, Inc. executives and directors. Shares of Vivos Therapeutics, Inc. have traded between $1.98 and $7.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vivos Therapeutics, Inc.. Vivos Therapeutics, Inc. is a $2.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vivos Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vivos Therapeutics, Inc.. Coverage tracks Vivos Therapeutics, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.